FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2107334098> ?p ?o ?g. }

• W2107334098 endingPage "161" @default.
• W2107334098 startingPage "155" @default.
• W2107334098 abstract "Abstract Purpose: Fludarabine, cyclophosphamide, and mitoxantrone (FCM) results in a high response rate in previously treated patients with chronic lymphocytic leukemia (CLL). The aim of this study was to investigate FCM as frontline therapy in CLL. Experimental Design: Sixty-nine patients under the age of 65 years with active CLL were treated. Patients received six cycles of fludarabine 25 mg/m2 i.v. × 3 days, cyclophosphamide 200 mg/m2 i.v. × 3 days, and mitoxantrone 6 mg/m2 i.v. × 1 day. Treatment outcome was correlated with clinical and biological variables. The clinical significance of eradicating minimal residual disease (MRD) was also analyzed. Results: The overall response, MRD-negative complete response (CR), MRD-positive CR, nodular partial response (PR), and PR rates were 90%, 26%, 38%, 14%, and 12%, respectively. Severe (grades 3 or 4) neutropenia developed in 10% of the patients. Major and minor infections were reported in 1% and 8% of cases, respectively. Median response duration was 37 months. Patients with del(17p) failed to attain CR. Patients achieving MRD-negative CR had a longer response duration and overall survival than patients with an inferior response. Low serum lactate dehydrogenase levels, low ZAP-70 expression, and mutated IgVH genes predicted longer response duration. Finally, both low ZAP-70 and CD38 expression in leukemic cells correlated with MRD-negativity achievement. Conclusion: FCM induces a high response rate, including MRD-negative CRs in untreated patients with active CLL. Treatment toxicity is acceptable. Both high ZAP-70 and increased CD38 expression predict failure to obtain MRD-negative response. Patients in whom MRD can be eradicated have longer response duration and overall survival than those with inferior response. These results indicate that FCM can be an ideal companion for chemoimmunotherapy of patients with CLL." @default.
• W2107334098 created "2016-06-24" @default.
• W2107334098 creator A5016510706 @default.
• W2107334098 creator A5020702876 @default.
• W2107334098 creator A5024516606 @default.
• W2107334098 creator A5024944985 @default.
• W2107334098 creator A5027401229 @default.
• W2107334098 creator A5034116023 @default.
• W2107334098 creator A5036998366 @default.
• W2107334098 creator A5037995027 @default.
• W2107334098 creator A5048566051 @default.
• W2107334098 creator A5050469395 @default.
• W2107334098 creator A5050933998 @default.
• W2107334098 creator A5052695708 @default.
• W2107334098 creator A5053280136 @default.
• W2107334098 creator A5054008156 @default.
• W2107334098 creator A5061167008 @default.
• W2107334098 creator A5068240503 @default.
• W2107334098 creator A5069901819 @default.
• W2107334098 creator A5076822049 @default.
• W2107334098 creator A5081688805 @default.
• W2107334098 creator A5084199325 @default.
• W2107334098 date "2008-01-01" @default.
• W2107334098 modified "2023-10-18" @default.
• W2107334098 title "Fludarabine, Cyclophosphamide, and Mitoxantrone as Initial Therapy of Chronic Lymphocytic Leukemia: High Response Rate and Disease Eradication" @default.
• W2107334098 cites W168625184 @default.
• W2107334098 cites W1963690972 @default.
• W2107334098 cites W1967577450 @default.
• W2107334098 cites W2061000716 @default.
• W2107334098 cites W2070193300 @default.
• W2107334098 cites W2073873436 @default.
• W2107334098 cites W2075942256 @default.
• W2107334098 cites W2078673385 @default.
• W2107334098 cites W2086637735 @default.
• W2107334098 cites W2111403010 @default.
• W2107334098 cites W2116248495 @default.
• W2107334098 cites W2117648265 @default.
• W2107334098 cites W2123103213 @default.
• W2107334098 cites W2123528154 @default.
• W2107334098 cites W2125134816 @default.
• W2107334098 cites W2126442701 @default.
• W2107334098 cites W2126796352 @default.
• W2107334098 cites W2129285584 @default.
• W2107334098 cites W2129945230 @default.
• W2107334098 cites W2132238257 @default.
• W2107334098 cites W2134057518 @default.
• W2107334098 cites W2135270635 @default.
• W2107334098 cites W2137804513 @default.
• W2107334098 cites W2142741025 @default.
• W2107334098 cites W2147894599 @default.
• W2107334098 cites W2153334574 @default.
• W2107334098 cites W2156824251 @default.
• W2107334098 cites W2160256220 @default.
• W2107334098 cites W2161926682 @default.
• W2107334098 cites W2275948481 @default.
• W2107334098 cites W2318261848 @default.
• W2107334098 cites W2318933236 @default.
• W2107334098 cites W2323490326 @default.
• W2107334098 cites W2323897083 @default.
• W2107334098 cites W2326175431 @default.
• W2107334098 cites W2587310790 @default.
• W2107334098 cites W319074543 @default.
• W2107334098 cites W4293241248 @default.
• W2107334098 cites W4376595664 @default.
• W2107334098 cites W60865865 @default.
• W2107334098 cites W96780237 @default.
• W2107334098 doi "https://doi.org/10.1158/1078-0432.ccr-07-1371" @default.
• W2107334098 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18172266" @default.
• W2107334098 hasPublicationYear "2008" @default.
• W2107334098 type Work @default.
• W2107334098 sameAs 2107334098 @default.
• W2107334098 citedByCount "121" @default.
• W2107334098 countsByYear W21073340982012 @default.
• W2107334098 countsByYear W21073340982013 @default.
• W2107334098 countsByYear W21073340982014 @default.
• W2107334098 countsByYear W21073340982015 @default.
• W2107334098 countsByYear W21073340982016 @default.
• W2107334098 countsByYear W21073340982017 @default.
• W2107334098 countsByYear W21073340982018 @default.
• W2107334098 countsByYear W21073340982019 @default.
• W2107334098 countsByYear W21073340982020 @default.
• W2107334098 countsByYear W21073340982023 @default.
• W2107334098 crossrefType "journal-article" @default.
• W2107334098 hasAuthorship W2107334098A5016510706 @default.
• W2107334098 hasAuthorship W2107334098A5020702876 @default.
• W2107334098 hasAuthorship W2107334098A5024516606 @default.
• W2107334098 hasAuthorship W2107334098A5024944985 @default.
• W2107334098 hasAuthorship W2107334098A5027401229 @default.
• W2107334098 hasAuthorship W2107334098A5034116023 @default.
• W2107334098 hasAuthorship W2107334098A5036998366 @default.
• W2107334098 hasAuthorship W2107334098A5037995027 @default.
• W2107334098 hasAuthorship W2107334098A5048566051 @default.
• W2107334098 hasAuthorship W2107334098A5050469395 @default.
• W2107334098 hasAuthorship W2107334098A5050933998 @default.
• W2107334098 hasAuthorship W2107334098A5052695708 @default.
• W2107334098 hasAuthorship W2107334098A5053280136 @default.
• W2107334098 hasAuthorship W2107334098A5054008156 @default.
• W2107334098 hasAuthorship W2107334098A5061167008 @default.

• next